Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8900559 | 0.81 | MTNR1A (0.57) | CTNNB1MTNR1AL3MBTL1TDP1MEN1 | |
| SCHEMBL5697803 | 0.78 | CTNNB1 (0.51) | CTNNB1MTNR1AL3MBTL1TDP1MMP9 | |
| SCHEMBL7598170 | 0.78 | KDM4E (0.47) | CTNNB1L3MBTL1TDP1KMT2AHRH4 | |
| SCHEMBL31175978 | 0.78 | FOLH1 (0.44) | L3MBTL1TDP1FOLH1 | |
| SCHEMBL9556813 | 0.78 | PARP10 (0.51) | CTNNB1MTNR1AL3MBTL1TDP1MEN1 | |
| SCHEMBL9556809 | 0.78 | PARP10 (0.51) | CTNNB1MTNR1AL3MBTL1TDP1MEN1 | |
| SCHEMBL5707319 | 0.76 | MMP9 (0.52) | CTNNB1MTNR1AL3MBTL1TDP1MMP9 | |
| SCHEMBL1284854 | 0.72 | CTNNB1 (0.54) | CTNNB1MTNR1AL3MBTL1TDP1MMP9 | |
| SCHEMBL30444809 | 0.72 | FOLH1 (0.39) | FOLH1MEN1KMT2A | |
| SCHEMBL10521682 | 0.72 | SIGMAR1 (0.51) | CTNNB1TDP1FOLH1KMT2AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | CTNNB1 3148/4885MTNR1A 4191/4885L3MBTL1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.